Skip to main content

Table 3 Outcome measures in the EXERPHARMA trial

From: The effect on knee-joint load of instruction in analgesic use compared with neuromuscular exercise in patients with knee osteoarthritis: study protocol for a randomized, single-blind, controlled trial (the EXERPHARMA trial)

 

Collection time points

Primary end point

 

Knee biomechanics (mean ±95% CI):

0, 8 weeks

  Knee index, during gait

 

Secondary end points:

 

Knee biomechanics (mean ±95% CI):

0, 8 weeks

  Knee Index, during one-leg rise

 

  Peak Knee Adduction Moment, during gait

 

  Peak Knee Adduction Moment, during one-leg rise

 

  Knee Adduction Moment Impulse, during gait

 

  Knee Adduction Moment Impulse, during one-leg rise

 

Functional performance test (mean ±95% CI):

0, 8 weeks

  Maximum one-leg rises from stool

 

  Maximum number of knee-bendings in 30-second test

 

  One-leg hop for distance test

 

Patient-reported outcomes:

 

Mean KOOS subscale scores (mean ±95% CI):

0, 8, 52 weeks

  Pain

 

  Other symptoms

 

  Activities of Daily Living (ADLs)

 

  Sport and Recreation Function

 

  Knee-related Quality of Life (QOL)

 

Activity level:

 

  UCLA activity score, change from baseline

0, 8, 52 weeks

Pain level:

 

  Pain-level text messages, intensity (0–4)

During treatment